Meloxicam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Meloxicam

Examples of brand names: Mobec [DE]

ATC code: M01AC06

Main use (for orientation): Pain; inflammation

Documented research summary

The CYP2C9/3A4 inhibition hypothesis is biologically plausible, but not isolated human pharmacokinetic evidence for meloxicam with a cannabinoid. Veterinary studies show no established additional benefit of the combination over monotherapy; the newer extract study does not allow attribution to individual substances.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0364

Type of result: Preclinical evidence

Observation: No demonstrated additional analgesic benefit of CBD plus meloxicam over monotherapies in perioperative dog studies.

Mechanism: Pharmacodynamic combination assessment; no pharmacokinetic measurement.

Study type: Randomised veterinary studies

Context studied: 60 or 64 dogs, ovariohysterectomy, CBD 2 mg/kg orally every 12 hours and meloxicam initially 0.2 mg/kg intravenously/0.1 mg/kg daily, 48 hours. Pupillometry/Glasgow scale or thermography.

Clinical interpretation: No human recommendation

Limitations and uncertainties: Small groups; same team, ethics number CBS.066.21 and similar populations/protocols: independence not established, so do not count as two independent confirmations. The thermography paper reverses G2/G3 between abstract and methods; the direction of some temperature details is inconsistent. No pharmacokinetic interaction or human tolerability established.

Original sources for this finding: Assessment of the nociceptive response to the use of cannabidiol alone and in combination with meloxicam through infrared pupillometry in female dogs undergoing elective ovariohysterectomy. [C_PR_39027908]; Assessing Facial Thermal Nociceptive Response in Female Dogs After Elective Ovariohysterectomy Anesthetized with Isoflurane and Treated with Cannabidiol and Meloxicam Analgesia. [C_PR_39858227]

CBD/CBDA/THC/THCA (extract) – laboratory and animal studies

Finding ID: B0365

Type of result: Preclinical evidence with substantial limitations

Observation: 2026 osteoarthritis dog study: cannabis group significantly different from conventional control at day 28, but NOT from placebo; not an isolated meloxicam combination effect.

Mechanism: Unseparated additional therapy within multimodal analgesia.

Study type: Randomised exploratory veterinary study

Context studied: 27 dogs, 9 per group, 6 weeks. Variable background therapy with meloxicam/carprofen/firocoxib and pregabalin. Cannabis versus placebo at day 28 p=0.493; versus control p=0.019.

Clinical interpretation: Hypothesis-generating, not clinically transferable

Limitations and uncertainties: No meloxicam subgroup analysis. Contradictory dose text: 1.16 versus 2.32 mg/drop, per dose versus daily dose; different baseline values, small sample. Do not present abstract percentages as established superiority. No general safety conclusion.

Original sources for this finding: Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral Cannabis sativa Oil Extract, Standardized Based on CBD-A, CBD and THC-A, THC in Canines with Chronic Osteoarthritis. [C_PR_41897881]

References and access status

[C_LABEL_D0168_UK] Meloxicam 15 mg Tablets, Flamingo Pharma UK SmPC

Original source / bibliographic reference

Authors: Flamingo Pharma UK Ltd.

Year: 2023

Source type: Official UK SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_39027908] Assessment of the nociceptive response to the use of cannabidiol alone and in combination with meloxicam through infrared pupillometry in female dogs undergoing elective ovariohysterectomy.

Original source / bibliographic reference

Authors: Casas-Alvarado A, Martínez-Burnes J, Hernández-Ávalos I, Mora-Medina P, Miranda-Cortés A, Domínguez-Oliva A, Mota-Rojas D.

Year: 2024

Source type: Primary source, full text read

DOI: 10.3389/fvets.2024.1380022

PMID: 39027908

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_39858227] Assessing Facial Thermal Nociceptive Response in Female Dogs After Elective Ovariohysterectomy Anesthetized with Isoflurane and Treated with Cannabidiol and Meloxicam Analgesia.

Original source / bibliographic reference

Authors: Casas-Alvarado A, Mora-Medina P, Hernández-Avalos I, Martínez-Burnes J, Miranda-Cortes A, Domínguez-Oliva A, Mota-Rojas D.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3390/ani15020227

PMID: 39858227

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_41897881] Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral Cannabis sativa Oil Extract, Standardized Based on CBD-A, CBD and THC-A, THC in Canines with Chronic Osteoarthritis.

Original source / bibliographic reference

Authors: Benjamin ET, Maria Teresa SE, Alexander NS, Stephanie SA, Martín SC, Sylvia AB.

Year: 2026

Source type: Primary source, full text read

DOI: 10.3390/ani16060900

PMID: 41897881

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_40480045] Facial action units as biomarkers of postoperative pain in ovariohysterectomized bitches treated with cannabidiol and meloxicam.

Original source / bibliographic reference

Authors: Casas-Alvarado A, Martínez-Burnes J, Mora-Medina P, Hernández-Avalos I, Miranda-Cortes A, Domínguez-Oliva A, Mota-Rojas D.

Year: 2025

Source type: Primary source, abstract read

DOI: 10.1016/j.rvsc.2025.105734

PMID: 40480045

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility